Business Context and Reporting Period
This Form 8-K Current Report was filed by Tivic Health Systems, Inc. (not Valion Bio, Inc.) on June 17, 2024. The report details corporate governance changes, specifically the appointment of a new director and the resignation of an existing director, effective July 1, 2024, and September 30, 2024, respectively. The filing also establishes the record date and proposal deadlines for the 2024 Annual Meeting of Stockholders.
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance and regulatory disclosures rather than financial performance.
Material Changes
- Board Appointment: Christina Valauri was appointed to the Board of Directors, effective July 1, 2024, to fill a Class I vacancy. She joins the Compensation, Audit and Risk, and Nominations and Corporate Governance Committees and will chair the Nominations and Corporate Governance Committee.
- Board Resignation: Karen Drexler resigned from the Board and all committee memberships, effective September 30, 2024. The resignation is not due to any disagreement with the Company regarding operations or policies.
- Annual Meeting Logistics: The 2024 Annual Meeting is scheduled for August 9, 2024, with June 17, 2024, as the record date. The deadline for shareholder proposals and director nominations is June 27, 2024.
Guidance, Outlook, and Risks
The filing contains standard forward-looking statements regarding risks and uncertainties that could cause actual results to differ from expectations. No specific financial guidance or operational outlook is provided in this document. The Company notes that Ms. Drexler is expected to continue serving as an advisor post-resignation.
Key Facts for Investor Verification
- Verify the effective dates of the board changes: Christina Valauri's appointment (July 1, 2024) and Karen Drexler's resignation (September 30, 2024).
- Confirm the deadline for submitting shareholder proposals and director nominations for the August 9, 2024, Annual Meeting (June 27, 2024).
- Note that no equity grants or special compensation arrangements were made to Ms. Valauri in connection with her appointment.
- Review the associated Press Release (Exhibit 99.1) for additional context on the board changes.